Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Lila Tarmin

Gastroenterology Baltimore, MD Medical Doctor

NPI 1669466108 CMS profile 29638

1838 Greene Tree Rd, Ste 400, Baltimore, MD 21208

Open in the dashboard

General payments

$5,454

364 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Lila Tarmin of Baltimore, MD is reported in the CMS Open Payments database as having received $5,454 across 364 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $741 41
2023 General $518 37
2022 General $936 50
2021 General $1,248 98
2020 General $616 48
2019 General $1,396 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lila Tarmin
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Lila Tarmin were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Lila Tarmin Gastroenterology median Middle half National median
2019 $1,396 $417 $126–$1,100 $163
2020 $616 $224 $74–$624 $114
2021 $1,248 $352 $106–$1,054 $132
2022 $936 $448 $129–$1,270 $149
2023 $518 $533 $150–$1,390 $160
2024 $741 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $2,486 187 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $678 38 payments
  3. Janssen Biotech, Inc. $448 25 payments
  4. Ironwood Pharmaceuticals, Inc $308 27 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $216 18 payments
  6. Gilead Sciences, Inc. $170 8 payments
  7. QOL Medical, LLC $140 8 payments
  8. Braintree Laboratories, Inc. $121 8 payments
  9. Pfizer Inc. $107 6 payments
  10. Janssen Scientific Affairs, LLC $103 1 payment
  11. Other $679 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,454 364 payments
Products named General payments · program years 2019–2024
  1. HUMIRA $1,143 81 payments
  2. STELARA $523 25 payments
  3. RINVOQ $504 34 payments
  4. CREON $472 50 payments
  5. ENTYVIO $408 18 payments
  6. LINZESS Gastroenterology $378 38 payments
  7. SKYRIZI $264 17 payments
  8. Linzess Gi $260 24 payments
  9. XIFAXAN $186 16 payments
  10. MAVYRET $177 8 payments
  11. Other $2,242 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

703

Median for Gastroenterology: 569

Drug cost

$74,132

Median for Gastroenterology: $104,976

Branded share of claims

33.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 41 $41,384
Mesalamine Generic 20 $10,751
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 145 $8,426
Dexlansoprazole Dr Dexlansoprazole Brand 11 $3,172
Lansoprazole Generic 60 $2,588
Famotidine Generic 172 $2,519
Pantoprazole Sodium Generic 91 $1,239
Colestipol Hcl Generic 11 $1,237
Sucralfate Generic 52 $821
Omeprazole Generic 44 $693

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$193,296

Medicare's payments for the services billed

Medicare patients

544

Average age 73

Services billed

6,377

432 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 38%
Depression 24%
Ischemic heart disease 22%
Chronic kidney disease 21%
Osteoporosis 20%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $184
$184 — —
SKYRIZI
  • AbbVie, Inc. $96
$96 — —
RINVOQ
  • AbbVie, Inc. $79
$79 — —
STELARA
  • Janssen Biotech, Inc. $53
$53 — —
DUPIXENT
  • GENZYME CORPORATION $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

364 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record